Tuesday, July 21, 2026, 11:00-11:30 AM CT
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2025—Eric Huang, MD, PhD, is the first to admit that when it came time to switch to primary HPV testing, his laboratory at the University of Washington faced fewer obstacles than most. Dr. Huang joined the university in 2018 as director of the cytopathology laboratory.
January 2025—In the 2024 edition of the CAP accreditation checklists, released on Dec. 26, laboratories can expect to see small but significant changes to the all common, cytopathology, and microbiology checklists. These revisions and additions are meant to ensure test quality as more laboratories begin to offer primary HPV screening and p16/Ki-67 dual stain triage.
January 2025—Renal mass biopsy has become an indispensable pre-management diagnostic tool, especially as incidental renal masses are increasingly detected with modern imaging techniques. It offers the patient the opportunity to get a definitive diagnosis without necessitating nephrectomy, especially helpful for patients with advanced disease or those who are poor surgical candidates. This is crucial, as certain renal cell carcinoma (RCC) subtypes have significantly different prognostic outcomes and therapeutic implications, making it essential to subtype RCCs in addition to distinguishing between benign and malignant lesions. For instance, systemic treatment strategies diverge markedly between clear cell RCC and non-clear cell RCC subtypes, underscoring our role in guiding personalized therapy choices. This article synthesizes key findings and diagnostic challenges most encountered on renal mass biopsy, with a focus on clear cell RCC, clear cell papillary renal cell tumor, TFE3-rearranged RCC, papillary RCC, oncocytoma, and chromophobe RCC.
January 2025—It is well documented that the cytologist/cytotechnologist workforce is diminishing and the number of training programs has declined. According to the Centers for Medicare and Medicaid Services, CT participation in gynecologic proficiency testing has decreased by 27 percent since 2005. New board certifications of CTs or specialists in CT(SCT) decreased by about 56 percent over the same period. CT(ASCP) and all SCT(ASCP) certifications are now recognized by the CMS and the Centers for Disease Control and Prevention per 42 CFR §493.1483.
January 2025—The traditional image of a pathologist is often that of a scientist working in a laboratory, handling chemical solutions, or peering through a microscope. Over the past decade, pathologists, including those specializing in cytopathology, have increasingly moved beyond those confines, taking on more prominent roles in patient-facing care. This article explores the various ways cytopathologists are expanding their roles, engaging directly with patients and physicians and positioning themselves at the forefront of the management team.
November 2024—New this month from CAP Publications is the CAP Practical Guide to Gynecologic Cytopathology—Morphology, Management, and Molecular Methods, second edition. Its 15 chapters cover squamous and glandular epithelial abnormalities, anal cytology, benign changes and mimics of premalignant and malignant epithelial lesions, and much more. In this issue we provide part of the chapter on look-alikes and morphologic spectrums of change.
September 2024—In HPV primary screening, self-collected vaginal samples enable accurate clinical HPV testing, and neither extended ambient dry storage nor exposure to extreme temperatures influence HPV detection, say the authors of a study published in June.
August 2024—Case. A 58-year-old female patient undergoes robotic endobronchial ultrasound-guided fine-needle aspiration for a peripherally located right upper lobe stellate-shaped lung lesion with ground-glass opacification. Rapid onsite evaluation (ROSE) assessments were adequate on four Diff-Quik (DQ) smears that were prepared for evaluation. One slide was cover-slipped for diagnostic purposes and the remaining slides were retained, uncovered. The cytopathologist requested additional material for further ancillary studies. The needle was rinsed in CytoLyt solution used to prepare a cell block from the cell pellet, and the residual supernatant was stored (at -80°C) for possible future molecular studies. The cell block cellularity was adequate, and the malignant cell population represented 50 percent of the sampled cells.
August 2024—The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a widely endorsed and increasingly adopted standardized reporting system for salivary gland fine-needle aspiration biopsy specimens. The inaugural edition published in 2018 was inspired by the Bethesda cervicovaginal and thyroid reporting systems. The MSRSGC sought to facilitate clear and consistent communication between pathologists and the clinical team, thereby enhancing patient-centered decision-making and therapeutic interventions and assisting inter- and intralaboratory comparisons.
August 2024—Two to five percent of pancreatic tumors are pancreatic neuroendocrine neoplasms, of which more than 90 percent are well-differentiated pancreatic neuroendocrine tumors (PanNETs). The current World Health Organization classification stratifies PanNETs into three histological grades based on mitotic count and Ki-67 proliferation index. Low-grade PanNETs (grades one and two) are morphologically indistinguishable and have characteristic neuroendocrine cytomorphologic features: a dispersed/loosely cohesive smear pattern composed of small-to-medium monomorphic cells with occasional plasmacytoid appearance; amphophilic, granular, or vacuolated cytoplasm; round nuclei; and coarse salt-and-pepper chromatin.
